Becatecarin

Summary

Becatecarin (CHEMBL2107313) is a phase-3 clinical-stage small molecule; indicated across 12 conditions including male breast carcinoma and small cell lung carcinoma.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• Indications: 12 conditions
• Clinical trials: 13
• Chemistry: 669.5 Da · C33H34Cl2N4O7

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL2107313
Name	Becatecarin
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	101524
Molecular formula	C33H34Cl2N4O7
Molecular weight	669.5
InChIKey	JSKFWUPVIZYJMR-UDOAKELVSA-N

SMILES: CCN(CC)CCN1C(=O)C2=C3C4=C(C(=CC=C4)Cl)NC3=C5C(=C2C1=O)C6=C(N5[C@H]7[C@@H]([C@H]([C@@H]([C@H](O7)CO)OC)O)O)C(=CC=C6)Cl

IUPAC name: 5,21-dichloro-13-[2-(diethylamino)ethyl]-3-[(2R,3R,4R,5S,6R)-3,4-dihydroxy-6-(hydroxymethyl)-5-methoxyoxan-2-yl]-3,13,23-triazahexacyclo[14.7.0.02,10.04,9.011,15.017,22]tricosa-1,4(9),5,7,10,15,17(22),18,20-nonaene-12,14-dione

Also known as: Becatecarin, Becatecarina, Becatecarine, BMS-181176, BMY-27557, Deae-rebeccamycin, NSC-655649, XL-119, XL119, BECATECARIN

Patent coverage: 81 distinct patent families (165 SureChEMBL compound mentions), from 3 matched compound structure(s). One matched structure accounts for 161 (98%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

10 diseases in clinical trials (phase 1–3, investigational — not approved indications). Highest ChEMBL trial phase per disease; a non-cancer approved use is occasionally logged at phase 3 here.

Disease (in trials)	Phase	MONDO	EFO
male breast carcinoma	2	MONDO:0005628	EFO:0006861
small cell lung carcinoma	2	MONDO:0008433	EFO:0000702
neuroblastoma	2	MONDO:0005072	EFO:0000621
kidney cancer	2	MONDO:0002367	MONDO:0002367
ovarian cancer	2	MONDO:0008170	MONDO:0008170
lung neoplasm	2	MONDO:0021117	MONDO:0008903
gallbladder neoplasm	2	MONDO:0021253	MONDO:0005411
colorectal neoplasm	2	MONDO:0005335	MONDO:0005575
neoplasm	1	MONDO:0005070	EFO:0000616
lymphoma	1	MONDO:0005062	EFO:0000574

2 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 13.

Phase distribution

Phase	Trials
PHASE2	9
PHASE1	3
PHASE3	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00090025	PHASE3	TERMINATED	XL119 Versus 5-Fluorouracil (5-FU) Plus Leucovorin (LV) in Subjects With Advanced Biliary Tumors
NCT00003737	PHASE2	COMPLETED	Rebeccamycin Analog in Treating Children With Relapsed or Refractory Neuroblastoma
NCT00005027	PHASE2	COMPLETED	Rebeccamycin Analog in Treating Patients With Advanced Kidney Cancer
NCT00005085	PHASE2	COMPLETED	Rebeccamycin Analog in Treating Patients With Metastatic or Locally Recurrent Colorectal Cancer
NCT00005817	PHASE2	COMPLETED	Rebeccamycin Analogue in Treating Women With Stage IIIB or Stage IV Breast Cancer
NCT00005997	PHASE2	TERMINATED	Rebeccamycin Analogue in Treating Patients With Advanced Liver and/or Biliary Cancer
NCT00006017	PHASE2	COMPLETED	Two Rebeccamycin Analogue Regimens in Treating Patients With Advanced or Recurrent Non-small Cell Lung Cancer
NCT00006102	PHASE2	COMPLETED	Rebeccamycin Analogue in Treating Children With Solid Tumors or Non-Hodgkin’s Lymphoma
NCT00006262	PHASE2	TERMINATED	Rebeccamycin Analogue in Treating Patients With Refractory Stage III or Stage IV Ovarian Epithelial Cancer
NCT00084487	PHASE2	TERMINATED	Rebeccamycin Analog as Second-Line Therapy in Treating Patients With Limited-Stage or Extensive-Stage Small Cell Lung Cancer That Relapsed After Previous First-Line Chemotherapy
NCT00004189	PHASE1	COMPLETED	Rebeccamycin Analog and Cisplatin With or Without Filgrastim in Treating Patients With Advanced Cancer
NCT00086983	PHASE1	TERMINATED	Rebeccamycin Analog and Oxaliplatin in Treating Patients With Refractory Solid Tumors
NCT00087204	PHASE1	COMPLETED	Rebeccamycin Analog in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, Acute Lymphoblastic Leukemia, or Chronic Myelogenous Leukemia

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).